Detalles de la búsqueda
1.
NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.
Br J Cancer
; 106(8): 1446-52, 2012 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22454080
2.
NT5E CpG island methylation is a favourable breast cancer biomarker.
Br J Cancer
; 107(1): 75-83, 2012 Jun 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-22653144
3.
The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma.
Br J Cancer
; 107(8): 1423-32, 2012 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-22955849
4.
Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab.
Pharmacogenomics J
; 12(6): 468-75, 2012 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21844885
5.
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Breast Cancer Res Treat
; 115(1): 87-99, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18483853
6.
Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG).
Anticancer Res
; 29(2): 745-51, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19331231
7.
The dawn of Clinical Oncology education in Greece.
J BUON
; 14(2): 327-32, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19650191
8.
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
Br J Cancer
; 99(11): 1775-85, 2008 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-18985033
9.
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Ann Oncol
; 19(5): 853-60, 2008 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-18042835
10.
Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study.
Cancer Chemother Pharmacol
; 62(2): 277-84, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-17901952
11.
Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive small-cell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group.
Lung Cancer
; 58(3): 355-61, 2007 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17698241
12.
Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study.
J Clin Oncol
; 18(17): 3101-7, 2000 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-10963638
13.
Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
J Clin Oncol
; 18(20): 3535-44, 2000 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-11032596
14.
Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol
; 21 Suppl 5: v228-31, 2010 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-20555087
15.
Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer.
Cancer Chemother Pharmacol
; 56(5): 521-8, 2005 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-15959778
16.
Syndrome of inappropriate antidiuretic hormone secretion due to recurrent oral cancer.
B-ENT
; 1(3): 151-3, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-16255500
17.
Metronomic vinorelbine: Anti-angiogenic activity in vitro in normoxic and severe hypoxic conditions, and severe hypoxia-induced resistance to its anti-proliferative effect with reversal by Akt inhibition.
Int J Oncol
; 47(2): 455-64, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26095084
18.
Cancer of Unknown Primary Origin.
Oncologist
; 2(3): 142-152, 1997.
Artículo
en Inglés
| MEDLINE | ID: mdl-10388044
19.
Cancers of unknown primary site: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol
; 20 Suppl 4: 154-5, 2009 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-19454441
20.
Diagnostic and therapeutic management of cancer of an unknown primary.
Eur J Cancer
; 39(14): 1990-2005, 2003 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12957453